BioVie Inc. (NASDAQ: BIVI) is set to host an investor webinar on November 7, 2024, at 4:15 p.m. ET, to discuss its pipeline of clinical programs targeting neurological, neurodegenerative disorders, and advanced liver disease. The event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will provide updates and answer questions about the company's progress.
Bezisterim's Potential in Neurodegenerative Diseases
BioVie's lead drug candidate, bezisterim (formerly NE3107), is a key focus. Bezisterim has demonstrated the ability to modulate TNFα production, which can lead to significant clinical improvements in Parkinson's disease (PD) and Alzheimer's disease (AD). Clinical studies have indicated that patients treated with bezisterim experienced reduced inflammation and insulin resistance, improved motor control and "morning on" symptoms in PD, and a slowing of cognitive decline with better brain imaging scans in AD, along with reduced DNA methylation levels.
Upcoming Clinical Trials
BioVie is planning several clinical trials to further evaluate bezisterim's efficacy. The company intends to launch a Phase 2b trial for PD in late 2024 or early 2025 and an exploratory Phase 2 trial for long COVID (LC) in early 2025, which is fully funded by a grant from the U.S. Department of Defense (DOD). Additionally, a Phase 3 trial for AD is planned for late 2025, utilizing a new once-daily formulation of bezisterim.
BIV201 for Ascites
BioVie is also developing BIV201 (continuous infusion terlipressin) for the treatment of ascites associated with advanced liver disease. The company is actively seeking a partner to commence a Phase 3 trial for BIV201. BIV201 has received FDA Fast Track status and is intended to reduce further decompensation in participants with liver cirrhosis and ascites.
About BioVie Inc.
BioVie Inc. is focused on developing innovative drug therapies for neurological and neurodegenerative disorders, including Long COVID, Alzheimer's disease, and Parkinson's disease, as well as advanced liver disease. The company's approach involves inhibiting inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor-κB, to address neuroinflammation and insulin resistance, which are key drivers of AD and PD.
